

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. LIT-PI-529D1		SERIAL NO. <u>618560</u> Filed Herewith	
LIST OF ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT William K. Koener		FILING DATE Filed Herewith	
				GROUP Unknown		<u>1648</u>	
U.S. PATENT DOCUMENTS							
*Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
	AA	5591829	01/07/97	Matsushita	530	391.1	
	AB	5633388	05/27/97	Diana et al	514	393	
	AC	5645836	07/08/97	Kitto	424	159.1	
	AD	5677274	10/14/97	Leppla et al	514	2	
	AE	5684024	11/04/97	Diana et al	548	365.4	
	AF	5767072	06/16/98	Vitetta et al	424	194.1	
	AG	5821243	10/13/98	Diana et al	544	238	
	AH	5830894	11/03/98	Pevear et al	514	243	
	AI	5834599	11/10/98	Chang et al	530	388.35	
	AJ	5935957	8/10/99	Diana et al	514	247	
AK	6333303	12/25/01	Borgford	514	2		
FOREIGN PATENT DOCUMENTS							
	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	AL	WO97/41233	11/6/97	PCT			
	AM						
	AN						
	AO						
	AP						
OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, Etc.)							
	AR	Lord, J.M., et al, "Ricin: Structure, Mode of Action, and Some Current Applications", <u>The FASEB Journal</u> , Vol.8 pp. 201and 206, 2/94.					
		Richardson, P.T, et al, "Recombinant Proricin Binds Galactose But Does Not Depurinate 28 S Ribosomal RNA," <u>FEBS 07564</u> , Vol 255, No. 1, page 15, 9/89.					
	AS	Westby, M.W., et al, "Preparation and Characterization of Recombinant, Proricin Containing an Alternative Protease-Sensitive Linker Sequence," <u>Bioconjugate Chemistry</u> , 1992, 3, p. 375.					
		Darket, P.L., et al., "Human Immunodeficiency Virus Protease," <u>Journal of Biological Chemistry</u> , Vol 264, No. 4, p. 2307 1989.					
	AT	Jordan, S.P., et al, "Activity and Dimerization of Human Immunodeficiency Virus Protease as a Function of Solvent Composition and Enzyme Concentration," <u>Journal of Biological Chemistry</u> , Vol. 267, No. 28, p. 20028, 1992.					
		Van Quen, M.G., "Rationale for the Use of Immunotoxins in the Treatment of HIV-Infected Humans," <u>Journal of Drug Targeting</u> , Vol 5, No. 2 p. 75, 1997.					
EXAMINER				DATE CONSIDERED <u>3/16/05</u>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. LIT-PI-529	SERIAL NO. Filed Herewith	
LIST OF ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT William K. Keener, et al		
				FILING DATE Filed Herewith	GROUP Unknown	
U.S. PATENT DOCUMENTS						
*Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
FOREIGN PATENT DOCUMENTS						
	Document Number	Date	Country	Class	Subclass	Translation
						Yes    No
	AL					
	AM					
	AN					
	AO					
	AP					
OTHER REFERENCES (including Author, Title, Date, Pertinent Pages, Etc.)						
<div style="font-size: 2em; margin: 0;"> </div>	AR		Wachinger, M., et al, "Bryodin, a Single-Chain Ribosome-Inactivating Protein, Selectively Inhibits the Growth of HIV-1-Infected Cells and Reduces HIV-1 Production," <u>Research in Experimental Medicine</u> , 193:1-2, 1993.			
			Till, M.A., et al, "'HIV-Infected Cells are Killed by rCF4-Ricin A Chain," <u>Science</u> , Vol. 24 p. 1166.			
<div style="font-size: 2em; margin: 0;"> </div>	AS					
<div style="font-size: 2em; margin: 0;"> </div>	AT					
EXAMINER			DATE CONSIDERED			
			3/16/05			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						